Their results show the potential to detect TP53 mutations in cfDNA of 49% of patients (with different tumor stages) and, more importantly, in the 35.7% of early-stage patients, demonstrating the potential of cfDNA as a promising tool for the early detection of SCLC patients with TP53 mutations. The gene discussed is TP53; the disease is small cell lung carcinoma.